Benzinga | Jul 15, 2021 08:50AM EDT

Lexaria Shares Are Trading Higher On Completion Of Antiviral Drug Molecular Characterization Study

* Lexaria Bioscience Corp (NASDAQ:LEXX) has announced results from its antiviral drug molecular characterization study VIRAL-MC21-1, completed by Canada's federally funded research organization, the National Research Council (NRC).

* The NRC has confirmed Lexaria's study objectives, demonstrating DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity.

* Each drug tested remained stable and did not undergo a change in chemical structure.

* The five drugs studied were remdesivir, ebastine, bepridil, rupintrivir, and colchicine.

* These findings support accelerated regulatory filings authorizations of prospective DehydraTECH-enabled, repurposed antiviral drugs.

* The Company will pursue collaboration opportunities with pharmaceutical partners to incorporate DehydraTECH technology with antiviral drugs, including or similar to those currently being investigated.

* Price Action: LEXX shares are up 9.5% at $7.3 during the premarket session on the last check Thursday.